Home

Insights

Novartis India Ltd P/E Ratio

Novartis India Ltd P/E Ratio

download
stocks purchased

₹ 0.1 Cr

Volume transacted

stocks purchased

0.7 K

stocks traded

Image

Novartis India Ltd

NSE: NOVARTIND

PE

31.6

Last updated : 20 Jun 04:44 AM

Key Highlights

    The P/E Ratio of Novartis India Ltd is 31.6 as of 20 Jun 04:44 AM .a1#The P/E Ratio of Novartis India Ltd changed from 32.7 on March 2019 to 13.5 on March 2023 . This represents a CAGR of -16.22% over 5 years. a1#The Latest Trading Price of Novartis India Ltd is ₹ 1089 as of 20 Jun 10:07 .a1#The PE Ratio of Trading Industry has changed from 24.8 to 44.1 in 5 years. This represents a CAGR of 12.20%a1# The PE Ratio of Automobile industry is 11.3. The PE Ratio of Finance industry is 31.6. The PE Ratio of IT - Software industry is 28.9. The PE Ratio of Retail industry is 142.7. The PE Ratio of Textiles industry is 7.2. The PE Ratio of Trading industry is 103.5. In 2024a1#The Market Cap of Novartis India Ltd changed from ₹ 1693 crore on March 2019 to ₹ 1395 crore on March 2023 . This represents a CAGR of -3.79% over 5 years. a1#The Revenue of Novartis India Ltd changed from ₹ 147.44 crore to ₹ 91.59 crore over 8 quarters. This represents a CAGR of -21.18% a1#The EBITDA of Novartis India Ltd changed from ₹ 58.32 crore to ₹ 21.63 crore over 8 quarters. This represents a CAGR of -39.10% a1#The Net Profit of Novartis India Ltd changed from ₹ 52.38 crore to ₹ 14.68 crore over 8 quarters. This represents a CAGR of -47.06% a1#The Dividend Payout of Novartis India Ltd changed from 47.67 % on March 2019 to 113.42 % on March 2023 . This represents a CAGR of 18.93% over 5 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '1932.7
Mar '20123.1
Mar '2165.2
Mar '220
Mar '2313.5

Fundamental Metrics

Market Cap

2,691 Cr

EPS

34.5

P/E Ratio (TTM) *

31.6

P/B Ratio (TTM) *

3.6

Day’s High

1096.9

Day’s Low

1080.05

DTE *

0.0

ROE *

11.4

52 Week High

1224.0

52 Week Low

599.95

ROCE *

16.5

* All values are consolidated

Last Updated time: 20 Jun 04:44 AM

* All values are consolidated

Last Updated time: 20 Jun 04:44 AM

Image

Novartis India Ltd

NSE: NOVARTIND

PRICE

1089.15

-1.00 (-0.09%)

stock direction

Last updated : 20 Jun 10:07

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Novartis India Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

Asset Value vs Market Value

Market Value

2,692

Asset Value

693

2.9 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Company NamePEMarket Cap (INR Cr.)
Adani Enterprises Ltd105371,703
Aegis Logistics Ltd4928,231
Cello World Ltd5719,088
Redington Ltd1316,796
Honasa Consumer Ltd12413,868
Novartis India Ltd312,691

Key Valuation Metric

Earnings

85 Cr

31.6 X

PE Ratio

Market Cap

₹2691Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

85 Cr

31.6 X

PE Ratio

Market Cap

₹2691Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Trading Industry over time

PE Ratio of Top Sectors

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '191693
Mar '201240
Mar '211363
Mar '221458
Mar '231396

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '22147
Sep '22108
Dec '2289
Mar '2393
Jun '23103
Sep '2396
Dec '23107
Mar '2492

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '2258
Sep '2223
Dec '2216
Mar '2326
Jun '2330
Sep '2334
Dec '2342
Mar '2422

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '2252
Sep '2218
Dec '228
Mar '2325
Jun '2320
Sep '2324
Dec '2327
Mar '2415

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '1948
Mar '20245
Mar '21118
Mar '22-663
Mar '23113

* All values are a in %

About Novartis India Ltd

About Novartis India Ltd

    Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947. The Company is focused on manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates in four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz. The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886. In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years. In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd. joined to form Novartis. In the year 1998, the company had set-up the Novartis Institute for Functional Genomics. During the year 2000, Novartis acquired the products Famvir and Vectavir/Denavir from SmithKline Beecham also in the same year, the company started to provide treatment to leprosy patients worldwide through World Health Organisation (WHO). Also in 2000, NIL had started JEET (Joint Effort to Eradicate Tuberculosis) with the aim of increasing awareness among TB patents and to involve doctors more actively in the fight against disease. After a year, Novartis Respiratory Research Centre, the largest of its kind in the world, was opened in Horsham (UK) in 2001 and also during the same year Novartis had entered into a partnership with the WHO to stem the spread of malaria in areas of the world were the diseases in endemic. The Glivec, a drug was launched by the company in April of the year 2002 in India. The Company bagged TERI corporate social responsibility award for the year 2002-03. Novartis united its generics businesses under one single global brand in the name of Sandoz during the year 2003 and also in the same year, the company was granted Exclusive Marketing Rights (EMR) for Glivec. In the year of 2005, the company and Astex Therapeutics formed an alliance to focus on novel cell cycle anti-cancer drugs and also NIL had debuted Citro-macalvit & Trioptal as new products for the year. During the year 2006 alone Novartis had spent about USD 755 million on research into neglected diseases and various patient-access programs. In August of the same year 2006, the company had filed a petition in the Madras High Court challenging the rejection of the Glivec patent and the same petition was dismissed by the Madras high court in August of the year 2007. In the identical year of 2007, NIL sold its Medical Nutrition business to Nestle. The Company had launched a new marketing initiative on National scale in September of the year 2008 named Arogya Parivar targeting the healthcare needs of villagers. New products and line extensions introduced during the period 2009-10 were Relmus , Coderan for Pain & Inflammation, Vinlep for Epilepsy and Givec HGC 100 mg for Oncology. Otrivin was re-launched as an OTC remedy in a new spray format and positioned as a convenient alternative to tablets. During the period 2013-14, the Company signed a Distribution Agreement with Nutri-Ad International NV, Belgium, for marketing and distribution of their poultry feed supplements in India and started distributing Adimix 30 Coated, Eurotiox 32 Premix, Salmonil Dry, Toxynil Dry and Nutrilac IGA. The Company also signed a Marketing and Distribution Agreement with Johnson and Johnson Limited, India, for marketing and distribution of their Ethicon sutures under the brand names Mersutures Catgut 1, Ethilon Nylon and Mersilk Silk for veterinary use in the cattle and canine segments.

Novartis India Ltd News Hub

News

Novartis India to conduct AGM

Novartis India announced that the 76th Annual General Meeting(AGM) of the company will be ...

Read more

11 May 202411:58

News

Board of Novartis India recommends Final Dividend

Novartis India announced that the Board of Directors of the Company at its meeting held on...

Read more

10 May 202417:41

News

Novartis India to conduct board meeting

Novartis India will hold a meeting of the Board of Directors of the Company on 10 May 2024...

Read more

27 Mar 202417:28

News

Novartis India Ltd leads losers in 'B' group

Pritish Nandy Communications Ltd, DB (International) Stock Brokers Ltd, Sarthak Metals Ltd...

Read more

20 Feb 202414:45

News

Novartis India to convene board meeting

Novartis India will hold a meeting of the Board of Directors of the Company on 25 January ...

Read more

28 Dec 202310:25

News

Novartis India to announce Quarterly Result

Novartis India will hold a meeting of the Board of Directors of the Company on 27 October ...

Read more

30 Sep 202315:41

Product Composition by Percentage (Revenue)

FAQs for PE of Novartis India Ltd

What is Novartis India Ltd current share price?

The current market price of Novartis India Ltd as of June 20, 2024 is ₹1089.15.

What is Novartis India Ltd's market cap?

Novartis India Ltd's market capitalisation stood at ₹2,691 Cr as of June 20, 2024

What are Novartis India Ltd's total net assets?

According to Novartis India Ltd's most recent financial filings, the company's net assets total ₹693.1 Cr.

Is Novartis India Ltd making a profit or loss?

Novartis India Ltd's net Profit as of June 20, 2024 is close to ₹85 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199